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Abstract
Background: Recurrent pneumonia (RP) is one of the most frequent causes of pediatric non-cystic fibrosis (CF)
bronchiectasis (BE) and a consequent accelerated decline in lung function. The aim of this study was to analyse the
clinical records of children with RP in attempt to identify factors that may lead to an early suspicion of non-CF BE.
Methods: We recorded the demographic and clinical data, and lung function test results of children without CF
attending our outpatient RP clinic between January 2009 to December 2013 who had undergone chest high-resolution
computed tomography ≥8 weeks after an acute pneumonia episode and ≤6 months before enrolment.
Results: The study involved 42 patients with RP: 21 with and 21 without non-CF BE. The most frequent underlying
diseases in both groups were chronic rhinosinusitis with post-nasal drip and recurrent wheezing (81 % and 71.4 %
of those with, and 85.7 % and 71.4 % of those without BE). FEV1 and FEF25–75 values were significantly lower in the
children with non-CF BE than in those without (77.9 ± 17.8 vs 96.8 ± 12.4, p = 0.004; 69.3 ± 25.6 vs 89.3 ± 21.9, p = 0.048).
Bronchodilator responsiveness was observed in seven children with BE (33.3 %) and two without (9.5 %; p = 0.13).
Conclusions: Reduced FEV1 and FEF25–75 values seem associated with an increased risk of developing non-CF BE in
children with RP. This suggests a need for further studies to confirm the diagnostic usefulness use of spirometry in
such cases.
Keywords: Bronchiectasis, Lower respiratory tract infections, Non-cystic fibrosis bronchiectasis, Pediatric pulmonology,
Pneumonia, Recurrent pneumonia
Background
The development of non-cystic fibrosis bronchiectasis
(non-CF BE), a chronic, progressive pulmonary disorder
characterised by the permanent dilatation of one or
more bronchi due to structural modifications in the
bronchial wall [1], is thought to be mainly due to
chronic inflammation of the lower respiratory tract. It is
frequently diagnosed in children living in developing
countries and those belonging to indigenous popula-
tions, including Australian aborigines, New Zealand
Maoris and Alaskan natives [2], but it is less frequent in
industrialised countries, probably because of differences
in genetic and environmental predisposing factors, better
hygiene and nutrition, greater vaccine coverage, and the
availability of effective antimicrobial drugs. However,
data collected in the UK [3, 4] and Italy [5] indicate that
it is not rare, although its prevalence is probably
underestimated mainly because it is only recently that
the advent of high-resolution computed tomography
(HRCT) has made it possible to identify cases that could
not be diagnosed by means of bronchograms [6].
In pediatric patients, non-CF BE causes an accelerated
decline in lung function that leads to repeated hospital ad-
missions due to acute infectious exacerbations, a poorer
quality of life, and possible premature death in early adult
life [7]. The early identification of children with non-CF
BE could therefore significantly improve their long-term
prognosis by delaying or preventing progressive lung func-
tion abnormalities. Kapur et al. retrospectively reviewed
the anthropometric and lung function data of 52 children
with non-CF BE aged ≥3 years, and found that they
remained stable for 3–5 years after the start of appropriate
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therapy [8]; however, exacerbations accelerated a decline
in lung function, thus suggesting that every effort should
be paid in order to ensure the early diagnosis of BE in
children with repeated or chronic respiratory problems.
Recurrent pneumonia (RP), which occurs in 6.7-8.2 %
of the general pediatric population in industrialised
countries, is frequently described in association with a
severe underlying disease favouring lung infections and
is considered a marker of the possible development of
non-CF BE [9–11]. However, it is often encountered in
children without significant risk factors [12], and this
can delay the diagnosis of non-CF BE itself, thus increas-
ing the risk of worsening lung function during adoles-
cence and adult life.
The aim of this study was to analyse the clinical records
of a group of children with RP in detail in an attempt to
identify factors that may lead to an early suspicion of non-
CF BE, so leading to prompt diagnosis and implementa-
tion of the best prophylactic and therapeutic measures.
Methods
Study design
This was a retrospective cohort study that involved chil-
dren regularly followed-up between January 2009 and
December 2013 in the Respiratory Disease Section of
the University of Milan (Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Milan, Italy) because of
RP. In accordance with Wald [13], RP was defined as at
least two episodes of radiographically confirmed alveolar
pneumonia in one year or more than three episodes at
any time, with radiographic clearance between episodes.
The alveolar pneumonia diagnoses were all confirmed
by chest radiographs evaluated by an independent expert
radiologist who classified the findings in accordance with
the World Health Organization criteria for the standard-
ized interpretation of pediatric chest radiographs for the
diagnosis of pneumonia [14]. According to a protocol
active in the Unit during the study period, 8–12 weeks
after the second episode of pneumonia all the children
with RP performed a chest radiograph and those who
did not show any evidence of pneumonia were eligible
for the study. Further criteria for selection were: 1)
absence of CF on the basis of a negative sweat test and
genetic analysis, 2) availability of the results of a chest
thoracic high-resolution computed tomography (HRCT)
performed ≥8 weeks after the last acute pneumonia
episode leading to RP diagnosis in order to avoid the risk
of diagnosing transient bronchial dilation and ≤6 months
before enrolment, 3) availability of all the demographic
and clinical data of each patient, including those relating
to evaluations of the possible cause of RP such as
immune disorders (including atopy and allergy); upper
airway problems such as chronic rhinosinusitis with
post-nasal drip, recurrent wheezing, tuberculosis, middle
lobe syndrome, congenital heart defects, and primary
ciliary dyskinesia (PCD) and 4) availability of the results
of the first pulmonary function test.
Ethics, consent and permissions
The study was approved by the Ethics Committee of
Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, Milan, Italy, and written informed consent was
obtained from the parent (s) or legal guardian (s) of each
study participant, and from the children aged >8 years.
Procedures
A record was made of all of the available demographic and
clinical data of each patient. Regarding underlying predis-
posing diseases, all the studied conditions were considered
only when a doctor diagnosed and documented their pres-
ence by radiological examination (i.e., chronic rhinosinusi-
tis, middle lobe syndrome, heart disease) and/or laboratory
test (i.e., allergy, immunodeficiencies). Chronic rhinosinu-
sitis was defined as the persistence of clinical symptoms of
rhinosinusitis for more than 90 days [15] and its diagnosis
was confirmed at the time of the HRCT. Middle lobe
syndrome was initially suspected because of chronic cough,
RP and chest X-ray evaluation showing atelectasis of the
right middle lobe and definitively confirmed by HRCT.
The HRCT was performed in any case following stand-
ard procedures. Inspiratory scans were from lung apices to
diaphragm with a scan thickness of 1 mm, and a scan
interval of 10 mm, with additional slices at 5-mm intervals
for areas of particular concern. Expiratory scans were at
intervals of 2–3 cm. A scan time of 1 sec was used. Image
windowing and levels were standard, at W-1,500, L-600.
Scans were reconstructed with a high-frequency (bone)
algorithm. Tube parameters were KVp 120, and mAs 50–
250. The smallest field of view that included the entire
width of the chest at the diaphragm on the inspiratory
scout view was used. Scans were independently evaluated
by a consultant pediatric radiologist blinded to the cases
HRCT scans were scored using a modification of the Bhalla
score [16]. The scoring system was as follows: 1) extent of
bronchiectasis (0 = none, 1 = one or partial broncho
pulmonary segment involved, 2 = two or more bronchopul-
monary segments involved, 3 = generalized cystic bronchi-
ectasis); 2) severity of bronchial dilatation (0 = normal, 1 =
less than twice the diameter of the adjacent pulmonary
artery, 2 =more than twice the diameter of adjacent
pulmonary artery); 3) severity of bronchial wall thickening
(0 = normal, 1 = 0.5 × the diameter of the adjacent pulmon-
ary artery, 2 = 0.5-1.0 × the diameter of the adjacent
pulmonary artery, 3 = ≥ 1.0 × the diameter of the adjacent
pulmonary artery); 4) presence of mucous plugging in large
airways (0 = none, 1 = present); 5) presence of mucous
plugging in small airways (0 = none, 1 = present); and 6)
extent of decreased attenuation (0 = normal, 1 = ≤ 50 % of
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lobar volume, 2= > 50 % of lobar volume). Scores ≤5 were
considered indicative of mild disease whereas scores be-
tween 6 and 10 and > 10 of moderate and severe disease,
respectively.
According to the protocol active in the Unit, the first
pulmonary function test was obtained from all of the clin-
ically stable patients not receiving drugs that could influ-
ence test results in the same day during which HRCT was
done. A HypAir Compaq spirometer (Medisoft, Belgium)
on the basis of the American Thoracic Society/European
Respiratory Society criteria was used [17]. The best
expected values of at least three reproducible ma-
noeuvres were considered, and forced vital capacity
(FVC), forced expiratory volume in 1 second (FEV1),
and forced expiratory flow 25-75 % (FEF25–75) were
recorded. After the baseline evaluation, the patients
were administered inhaled salbutamol (four 100 μg
doses) by means of a metered dose inhaler. A positive
bronchodilator response was defined as an improve-
ment in FEV1 of at least 12 % (or at least 200 mL) in
comparison with baseline. The results were expressed
as percentages of the predicted value using Zapletal’s
reference equation.
Statistical analysis
The continuous data were expressed as mean values ±
standard deviation [SD], and compared between groups
using a Wilcoxon rank-sum test after checking that the
data were normally distributed. The categorical data
were expressed as number and percentages and com-
pared using contingency table analysis and χ2 or Fisher’s
exact test, as appropriate. Odds ratios (OR) and 95 %
confidence intervals (CI) were calculated through un-
conditional multiple logistic regression models, adjusting
for age at diagnosis (using a continuous term). All of the
tests were two sided, and a p value of <0.05 was consid-
ered statistically significant. The data were analysed
using SAS version 9.1 software (Cary, NC, USA).
Results
Among the 435 patients regularly followed-up for RP, a
total of 42 were selected for the study. A total of 393
cases were excluded, in 358 cases because of CF and in
the remaining 35 because HRCT was done beyond the
established period of time. None of them had a history
of wet cough on a daily or regular basis at the time of
the HRCT. Table 1 shows the demographic characteris-
tics of the 42 enrolled patients with a history of RP: 21
had non-CF BE (14 males; mean age ± SD, 12.2 ±
4.5 years) and 21 normal HRCT findings (13 males;
mean age ± SD, 9.2 ± 3.9 years; p = 0.02). Mean age ± SD
at the time of the HRCT scan was significantly higher in
the children with BE (6.6 ± 2.9 vs 4.7 ± 3.0 years; p =
0.03), but gestational age, birth weight, the number of
patients with respiratory problems at birth, the number
of patients exclusively breastfed for >3 months, the
number of siblings, age at the beginning of day care at-
tendance, and exposure to passive smoking were similar
between the two groups. For the latter characteristics,
no significant difference between groups emerged even
after adjusting for age at diagnosis.
Table 2 shows the underlying diseases in the study
population. More than 90 % of the children enrolled in
the study had an underlying disease without any statisti-
cally significant difference between the patients with and
without non-CF BE. The most frequently reported dis-
eases were chronic rhinosinusitis with post-nasal drip
(17/21 children with BE, 81 %, and 15/21 without BE,
71.4 %) and recurrent wheezing (in 15/21 children with
BE, 71.4 %, and 18/21 without BE, 85.7 %). IgA defi-
ciency was diagnosed in 6 patients (3/21 children with
BE, 14.3 %, and 3/21 without BE, 14.3 %), whereas pri-
mary ciliary dyskinesia was diagnosed in one child only
with BE (1/21, 4.8 %). No cases of tuberculosis infection,
foreign body retention or airway malformation were de-
tected in either group.
Among the children with non-CF BE, the HRCT ab-
normalities were focal in 14 (66.6 %) and multifocal in
seven (33.4 %; unilateral in two and bilateral in five). In
most of the cases (18, 85.7 %) at least one abnormality
was evidenced in the same anatomical areas as the initial
pneumonia. The right side was slightly more frequently
involved than the left (56 % vs 44 %); the middle lobe
was involved in 32.3 %, the right and left lower lobes in
17.6 % each, the lingula in 11.7 %, the left upper lobe in
8.8 %, and the right upper lobe and left hilum in 5.9 %
each. The BE pattern was cylindrical in 18/21 patients
(85.7 %) and varicose in three (14.3 %). The presenting
symptoms at the time of HRCT scan were chronic pro-
ductive cough in 18/21 (85.7 %), crepitations in the same
lung area in four (19 %) and dyspnea in three (14.3 %).
None of the patients showed clubbing or hemoptysis.
According to HRCT scores, severity of bronchiectasis
was considered mild in eleven (52.4 %) cases, moderate
in seven (33.3 %), and severe in three (14.3 %).
Table 3 summarises the patients’ clinical history of lower
respiratory tract involvement and the results of their lung
function tests. All the children were entirely well between
pneumonia episodes and showed an increase in inflamma-
tory biomarkers (white blood cell count, neutrophils and
C reactive protein) during the pneumonia. Age at the time
of the first pneumonia episode, the number of pneumonia
episodes experienced before undergoing HRCT, and
the number of wheezing events per year were similar
in those with and without non-CF BE, but pulmonary
tests showed that the values of FEV1 and FEF25–75
were significantly lower in the children with non-CF BE
(p = 0.004 and p = 0.048, respectively). After adjustment
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for age, the results were still statistically significant. Fur-
thermore, seven of the children with BE (33.3 %) were
responsive to bronchodilators as against only two of those
without (9.5 %; p = 0.13).
Discussion
It has been demonstrated that RP early in life is a major
risk factor for BE [9], but only some children actually
develop BE after the first episodes of pneumonia. The
early identification of the patients at the highest risk of
BE could allow a diagnosis to be made when the bron-
chial wall lesions are still mild, thus favouring the imple-
mentation of appropriate preventive and therapeutic
measures, and a better final prognosis.
More than 90 % of the children involved in this study
had underlying clinical conditions that are usually
Table 1 Demographic characteristics of children with a history of recurrent pneumonia (RP), with and without non-cystic fibrosis
bronchiectasis (non-CF BE)
RP and non-CF BE (n = 21) RP alone (n = 21) P-value* OR (95 % CI)**
Gender, F:M 7:14 8:13
Mean age ± SD at enrolment, years 12.2 ± 4.5 9.2 ± 3.9 0.02
Mean age ± SD at diagnosis, years 6.6 ± 2.9 4.7 ± 3.0 0.03
Gestational age (weeks)
<32 1 (4.7 %) 4 (19.0 %) 0.33 (0.03-3.65)
32-36 2 (9.5 %) 2 (9.5 %) 1.05 (0.12-8.95)
≥37 18 (85.7 %) 15 (71.4 %) 0.35 1 (ref)
Birth weight (grams)
<2500 2 (10.0 %) 7 (33.3 %) 1 (ref)
≥2500 19 (90.5 %) 14 (66.7) 0.13 3.19 (0.53-19.2)
Respiratory distress at birth1
No 16 (80.0 %) 13 (61.9 %) 1 (ref)
Yes 4 (20.0 %) 8 (38.1 %) 0.20 0.54 (0.12-2.32)
Intubation at birtha
No 16 (84.2 %) 16 (76.2 %) 1 (ref)
Yes 3 (15.8 %) 5 (23.8 %) 0.70 0.79 (0.15-4.14)
Nasal CPAP at birtha
No 17 (89.5 %) 16 (76.2 %) 1 (ref)
Yes 2 (10.5 %) 5 (23.8 %) 0.41 0.57 (0.09-3.72)
Oxygen therapy at birtha
No 16 (84.2 %) 15 (71.4 %) 1 (ref)
Yes 3 (15.8 %) 6 (28.6 %) 0.46 0.64 (0.13-3.26)
Breastfeeding >3 monthsa
No 8 (40.0 %) 12 (57.1 %) 1 (ref)
Yes 12 (60.0 %) 9 (42.9 %) 0.27 1.94 (0.52-7.28)
No. of siblings
0 12 (57.1 %) 9 (42.9 %) 1 (ref)
1+ 9 (42.9 %) 12 (57.1 %) 0.35 0.52 (0.14-1.91)
Age at start of day care attendancea
<3 years 6 (31.6 %) 10 (52.6 %) 1 (ref)
≥3 years 13 (68.4 %) 9 (47.4 %) 0.19 2.06 (0.53-8.10)
Passive smoking exposure
No 15 (71.4 %) 10 (47.6 %) 1 (ref)
Yes 6 (28.6 %) 11 (52.4 %) 0.12 0.28 (0.07-1.16)
OR odds ratio, CI confidence interval, SD standard deviation, CPAP continuous positive airway pressure. aSome missing data. *χ2 or Fisher’s exact test (categorical
variables); Wilcoxon’s rank-sum test (continuous variables). Significant differences are reported in bold. **ORs from logistic regression models, adjusting for age
at diagnosis
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considered to be predisposing factors for the development
of RP. These were frequently common and only relatively
severe diseases such as chronic rhinosinusitis with post-
nasal drip and recurrent wheezing, whereas severe chronic
underlying diseases were rare. The presence of chronic rhi-
nosinusitis, that is often difficult to diagnose, is not surpris-
ing because sinus infections are very common childhood
and may give rise to a reservoir of bacterial pathogens that
chronically enter the lower airways [15, 18]. Furthermore,
recurrent wheezing may be associated with the spread of
viral pathogens from the upper to the lower respiratory
tract [19], thus contributing to further chronic inflamma-
tion [20, 21]. It is therefore clearly important to evaluate
the history of children with RP but, as rhinosinusitis and
wheezing are extremely common, their presence per se
does not immediately suggest the need for HRCT unless
they are associated with other, more severe conditions that
are known to increase the risk of BE. On the other hand,
after this study we have also decided to modify the protocol
active in our Unit and since 2014 we avoided to perform
HRCT in a child only for RP if there are no other clinical
indications to perform it.
Table 2 Underlying predisposing diseases in children with a history of recurrent pneumonia (RP), with and without non-cystic
fibrosis bronchiectasis (non-CF BE)
RP and non-CF BE (n = 21) RP alone (n = 21) P-value* OR (95 % CI)**
Chronic rhinosinusitis with post-nasal drip
No 4 (19.0 %) 6 (28.6 %) 1 (ref)
Yes 17 (81.0 %) 15 (71.4 %) 0.47 1.40 (0.30-6.45)
Atopy
No 8 (38.1 %) 9 (42.9 %) 1 (ref)
Yes 13 (61.9 %) 12 (57.1 %) 0.75 0.79 (0.20-3.21)
Total IgE at diagnosis, KU/L 291.8 ± 363.1 278.5 ± 20.9 0.60
Sensitisation to perennial allergens
No 14 (66.7 %) 17 (81.0 %) 1 (ref)
Yes 7 (33.3 %) 4 (19.0 %) 0.29 1.81 (0.41-7.93)
Wheezing
No 6 (28.6 %) 3 (14.3 %) 1 (ref)
Yes 15 (71.4 %) 18 (85.7 %) 0.45 0.31 (0.06-1.69)
IgA deficiency
No 18 (85.7 %) 18 (85.7 %) 1 (ref)
Yes 3 (14.3 %) 3 (14.3 %) 1 0.83 (0.14-5.09)
Primary ciliary dyskinesia
No 20 (95.2 %) 21 (100 %)
Yes 1 (4.8 %) 0 1 NC
Middle lobe syndrome
No 14 (66.7 %) 11 (52.4 %) 1 (ref)
Yes 7 (33.3 %) 10 (47.6 %) 0.35 0.66 (0.18-2.45)
Heart disease
No 18 (85.7 %) 18 (85.7 %) 1 (ref)
Yes 3 (14.3 %) 3 (14.3 %) 1 1.71 (0.26-11.2)
Tuberculosis infection
No 21 (100.0 %) 21 (100.0 %)
Yes 0 0 1 NC
Foreign body retention
No 21 (100.0 %) 21 (100.0 %)
Yes 0 0 1 NC
OR odds ratio, CI confidence interval, NC not computable
*χ2 or Fisher’s exact test (categorical variables); Wilcoxon’s rank-sum test (continuous variables). **ORs from logistic regression models, adjusting for age
at diagnosis
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The findings of this study seem to indicate that in a
relevant number of children with RP, independently
from its origin, non-CF BE is accompanied by reduction
in FEV1 and FEF25–75 values, and increased responsive-
ness to bronchodilators. It is possible that the fact that
the patients with non-CF BE were somewhat older than
those without BE may have influenced the lung function
results and the difference between the two group of
subjects. Moreover, the absence of significant differences
in responsiveness to bronchodilators can be explained
by the limited number of the study patients. However, as
inflammation characterises the pathogenesis of non-CF
BE, it can be assumed that allergic IgE-mediated inflam-
mation may play a concomitant role in damaging airway
tissue. Horváth et al. have shown that the level of
exhaled nitric oxide (FeNO), a non-invasive marker of
eosinophilic inflammation, is significantly increased in
adult patients with non-CF BE [22], and Narang et al.
found that median levels of FeNO are higher in children
with non-CF BE than in those with CF BE [23].
As we found that BE-related lesions were mainly local-
ised, and that the non-CF BE pattern was predominantly
mild, it can be hypothesised that these changes do not
significantly affect spirometric values and that children
with non-CF BE have pre-existing impaired lung func-
tion due to airflow obstruction, the small size of their
airways, or both. On the other hand, it is also possible
that our findings could reflect localized airway narrow-
ing where the BE is rather than generalized airway
narrowing. Regamey et al. recently documented an early
increase in airway smooth muscle mass in children with
BE [24]. The nature of the underlying chronic inflamma-
tion in the BE group was not specified, but the airway
alterations undoubtedly contributed to airway narrow-
ing. The authors also found a linear relationship between
airway smooth muscle content and bronchodilator
responses [24].
These findings needs confirmation with further studies
because they could have a number of practical
implications. The changes associated with non-CF BE
can originate early in life and so possible airway resist-
ance and inflammation should be evaluated even in very
young children with RP (particularly those without a se-
vere chronic underlying disease). Although we studied a
difficult to assess age-group and there could be some
limits in the repeatability of the measures, advances in
spirometry measurement techniques have made it pos-
sible to obtain spirometry in children as young as 3 years
of age with an appropriate repeatibility. Moreover, recently
spirometry centiles were created using the lambda, micro,
sigma (LMS) method extending previously published
equations down to the first years of life. This permits to
have reliable data also for younger children and to
adequately follow bronchial function modification during
development [25, 26].
The limitations of this study include its retrospective
nature, the relatively small number of subjects, and the
fact that variables such as FeNO and airway resistance
measurements were not recorded. Nevertheless, the find-
ing that bronchial obstruction seems to be associated with
an increased risk of developing non-CF BE development is
interesting, and suggests that further studies should be
carried in order to confirm the value of spirometry as a
means of raising the suspicion of non-CF BE in children
with RP.
Conclusions
Reduced FEV1 and FEF25–75 values seem to be an early
marker of an increased risk of developing non-CF BE in
children with RP.
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Table 3 Clinical history of lower respiratory tract involvement and lung function test results in children with a history of recurrent
pneumonia (RP), with and without non-cystic fibrosis bronchiectasis (non-CF BE)
RP and non-CF BE RP alone P-value* OR (95 % CI)**
Mean age ± SD at first pneumonia episode, years 2.0 ± 1.2 1.8 ± 1.6 0.35 1.07 (0.51-2.23)
Mean number of pneumonia episodes before HRCT ± SD 4.0 ± 3.2 4.1 ± 2.3 0.30 0.65 (0.34-1.25)
Mean number of wheezing events per year ± SD 4.5 ± 2.9 5.0 ± 3.3 0.60 0.90 (0.45-1.81)
First available lung function test results:
FVC (% of predicted value) 91.1 ± 15.8 100.5 ± 10.6 0.13 0.52 (0.24-1.13)
FEV1 (% of predicted value) 77.9 ± 17.8 96.8 ± 12.4 0.004 0.24 (0.07-0.78)
FEF25–75 (% of predicted value) 69.3 ± 25.6 89.3 ± 21.9 0.048 0.31 (0.11-0.84)
SD standard deviation, HRCT high-resolution computed tomography, FVC forced vital capacity; FEV1: forced expiratory volume in 1 second; FEF25–75: forced expiratory
flow from 25 % to 75 % of vital capacity. *χ2 or Fisher’s exact test (categorical variables); Wilcoxon’s rank-sum test (continuous variables). Significant differences are re-
ported in bold. ** ORs from logistic regression models for an increment equal to 1 SD, calculated in patients with RP alone, after adjustment for age at diagnosis
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